Antihypertensive Therapeutics Market Size, Share, Growth & Analysis Report 2020: Radiant Insights, Inc
GBI Research, the leading business intelligence provider, has released its latest research, ''Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries'', which provides in-depth analysis of hypertension therapeutics market within the eight major geographies of the US, the top five European countries (the UK, France, Germany, Spain and Italy), Japan and Canada. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. Browse Full Report With TOC @ http://www.radiantinsights.com/research/antihypertensive-therapeutics-in-major-developed-markets-to-2020-increased-uptake-of-combination-therapies-to-offset-effects-of-key-patent-expiries The value of the hypertension market in the major developed markets amounted to an estimated $40.0 billion in 2013 and is expected to decline during the forecast period at a negative Compound Annual Growth Rate (CAGR) of 0.9% to $37.6 billion in 2020, with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter. The initial growth will be due to the increased penetration of fixed-dose combination drugs (Amturnide, Exforge Tribenzor, Azor, Tekturna HCT, Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo, Valturna), a rise in the prevalence population from 181 million to 190 million at a CAGR of 0.6%, and two new expected launches in the pipeline (azilsartan + amlodipine, and AHU377+ valsartan). However, due to the expiry of the exclusivity of major drugs both before and during the forecast period (Cozaar in 2010; Diovan, Avapro and Atacand in 2012; Exforge in 2014; Benicar in 2016; and Tekturna and Tekturna HCT in 2018), increased generic penetration and a low diagnosis rate, the market will decline from 2017.
GBI Research, the leading business intelligence provider, has released its latest research, ''Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries'', which provides in-depth analysis of hypertension therapeutics market within the eight major geographies of the US, the top five European countries (the UK, France, Germany, Spain and Italy), Japan and Canada. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.
Browse Full Report With TOC @ http://www.radiantinsights.com/research/antihypertensive-therapeutics-in-major-developed-markets-to-2020-increased-uptake-of-combination-therapies-to-offset-effects-of-key-patent-expiries
The value of the hypertension market in the major developed markets amounted to an estimated $40.0 billion in 2013 and is expected to decline during the forecast period at a negative Compound Annual Growth Rate (CAGR) of 0.9% to $37.6 billion in 2020, with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter. The initial growth will be due to the increased penetration of fixed-dose combination drugs (Amturnide, Exforge Tribenzor, Azor, Tekturna HCT, Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo, Valturna), a rise in the prevalence population from 181 million to 190 million at a CAGR of 0.6%, and two new expected launches in the pipeline (azilsartan + amlodipine, and AHU377+ valsartan). However, due to the expiry of the exclusivity of major drugs both before and during the forecast period (Cozaar in 2010; Diovan, Avapro and Atacand in 2012; Exforge in 2014; Benicar in 2016; and Tekturna and Tekturna HCT in 2018), increased generic penetration and a low diagnosis rate, the market will decline from 2017.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
2.5.5 Diagnosis of Target Organ Damage 12<br />
2.5.6 Diagnosis of Hypertension in Pregnancy 12<br />
2.6 Classification 12<br />
2.7 Epidemiology 13<br />
2.8 Prognosis 14<br />
2.9 Treatment and Management 14<br />
2.9.1 Treatment Strategy 15<br />
Browse Full <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/antihypertensivetherapeutics-in-major-developed-markets-to-<strong>2020</strong>-increased-uptake-of-combination-therapies-tooffset-effects-of-key-patent-expiries<br />
3 <strong>Market</strong>ed Products 19<br />
3.1 Approved Products 19<br />
3.1.1 Norvasc (amlodipine besylate) - Pfizer 19<br />
3.1.2 Micardis (telmisartan) - Boehringer Ingelheim 21<br />
3.1.3 Tekturna (aliskiren) - Novartis/Speedel 22<br />
3.1.4 Benicar (olmesartan medoxomil) - Daiichi Sankyo 24<br />
3.1.5 Diovan (valsartan) - Novartis 25<br />
3.1.6 Cozaar (losartan) - Merck 27<br />
3.1.7 Exforge (amlodipine + valsartan) - Novartis 29<br />
3.2 Comparative Efficacy and Safety 31<br />
4 Product Pipeline 33<br />
4.1 Overall Pipeline 33<br />
4.2 Pipeline <strong>Analysis</strong> by Molecules Type 34<br />
4.3 Pipeline <strong>Analysis</strong> by Mechanism of Action Type 35<br />
4.4 Clinical Trial Failure Rate 37<br />
4.5 Patient Enrollment and Clinical Trial <strong>Size</strong> 39<br />
4.6 Clinical Trial Duration 40
Change language